LLY · News · 20260918N
Product / Drug Pipeline Progress
ELI LILLY & Co · 2026-09-18 · Importance 23 · Surprise 24 · In source text
Lilly is awaiting a September 30 readout for mid-stage data on eloraTZP, a two-drug obesity treatment. The reported results are expected to show whether the combination provides a meaningful improvement over existing weight-loss therapies or only incremental gains. The outcome could affect perceptions of Lilly’s obesity franchise and the commercial potential of its next-generation pipeline.
Key facts
- In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free survival compared to Inluriyo alone among patients with ESR1-mutated metastatic breast cancer. source
- The September 30 readout will reveal mid-stage data for eloraTZP, Eli Lilly's two-drug obesity combination. source
- Eli Lilly is staking its "trillion-dollar valuation" on mid-stage data for a two-drug obesity combo called eloraTZP, according to 247wallst.com. source
- Inluriyo (imlunestrant) is an oral estrogen receptor (ER) antagonist. source
- Eli Lilly stated the all-oral combination of Inluriyo and Verzenio has an established tolerability profile and requires no new monitoring. source
- A 247wallst.com headline characterizes Eli Lilly's valuation as "$1 Trillion" in relation to its two-drug obesity treatment. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free survival compared to Inluriyo alone… |
| revenue | unclear | probable | — | The September 30 readout will reveal mid-stage data for eloraTZP, Eli Lilly's two-drug obesity combination. |